Meg Elias

6.8k total citations · 1 hit paper
15 papers, 568 citations indexed

About

Meg Elias is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Meg Elias has authored 15 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Immunology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Meg Elias's work include CAR-T cell therapy research (13 papers), Biosimilars and Bioanalytical Methods (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Meg Elias is often cited by papers focused on CAR-T cell therapy research (13 papers), Biosimilars and Bioanalytical Methods (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Meg Elias collaborates with scholars based in United States, Netherlands and Tanzania. Meg Elias's co-authors include William Y. Go, Tanya Siddiqi, Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Yizhou Jiang, Jeff Aycock, John M. Rossi, Jeff Wiezorek and Adrian Bot and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Meg Elias

14 papers receiving 558 citations

Hit Papers

Phase 1 Results of ZUMA-1... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
    2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Meg Elias 536 151 149 131 130 15 568
Jeff Aycock 589 1.1× 170 1.1× 155 1.0× 142 1.1× 144 1.1× 24 624
Christina A. Bachmeier 518 1.0× 122 0.8× 129 0.9× 98 0.7× 117 0.9× 27 598
Danielle Vanasse 507 0.9× 142 0.9× 189 1.3× 158 1.2× 135 1.0× 7 549
Bindu George 417 0.8× 102 0.7× 156 1.0× 151 1.2× 136 1.0× 22 544
Elizabeth Halton 555 1.0× 187 1.2× 117 0.8× 141 1.1× 129 1.0× 29 604
Ian R. Hardy 423 0.8× 104 0.7× 185 1.2× 241 1.8× 161 1.2× 10 556
Barbara Pender 850 1.6× 277 1.8× 275 1.8× 242 1.8× 213 1.6× 9 885
Lori McIntyre 641 1.2× 179 1.2× 173 1.2× 220 1.7× 194 1.5× 8 700
Marika Sherman 397 0.7× 87 0.6× 111 0.7× 79 0.6× 102 0.8× 12 420
Birju Mehta 619 1.2× 234 1.5× 176 1.2× 170 1.3× 234 1.8× 17 683

Countries citing papers authored by Meg Elias

Since Specialization
Citations

This map shows the geographic impact of Meg Elias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meg Elias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meg Elias more than expected).

Fields of papers citing papers by Meg Elias

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meg Elias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meg Elias. The network helps show where Meg Elias may publish in the future.

Co-authorship network of co-authors of Meg Elias

This figure shows the co-authorship network connecting the top 25 collaborators of Meg Elias. A scholar is included among the top collaborators of Meg Elias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meg Elias. Meg Elias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2018). Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial. Biology of Blood and Marrow Transplantation. 24(3). S74–S75. 1 indexed citations
3.
Locke, Frederick L., Sattva S. Neelapu, Nancy L. Bartlett, et al.. (2017). Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy. 25(1). 285–295. 463 indexed citations breakdown →
4.
Locke, Frederick L., Sattva S. Neelapu, Nancy L. Bartlett, et al.. (2017). Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. Journal of Clinical Oncology. 35(15_suppl). 7512–7512. 24 indexed citations
5.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2017). AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1. Hematological Oncology. 35(S2). 28–28. 21 indexed citations
6.
Locke, Frederick L., Sattva S. Neelapu, Nancy L. Bartlett, et al.. (2017). Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Cancer Research. 77(13_Supplement). CT019–CT019. 15 indexed citations
7.
8.
9.
Wang, M., Frederick L. Locke, Tanya Siddiqi, et al.. (2016). ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL). Annals of Oncology. 27. vi326–vi326. 7 indexed citations
10.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2016). ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Annals of Oncology. 27. vi325–vi325. 2 indexed citations
11.
12.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2016). Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 16. S102–S102. 1 indexed citations
13.
14.
15.
Mulder, NH, Phb Willemse, Jan G. Zijlstra, et al.. (1996). The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.. PubMed. 15(6B). 2851–6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeff Aycock Breakdown of academic impact, for papers by Christina A. Bachmeier Breakdown of academic impact, for papers by Danielle Vanasse Breakdown of academic impact, for papers by Bindu George Breakdown of academic impact, for papers by Elizabeth Halton Breakdown of academic impact, for papers by Ian R. Hardy Breakdown of academic impact, for papers by Barbara Pender Breakdown of academic impact, for papers by Lori McIntyre Breakdown of academic impact, for papers by Marika Sherman Breakdown of academic impact, for papers by Birju Mehta
Rankless by CCL
2026